From the Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Department of Nuclear Medicine, Fujian Provincial Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Clin Nucl Med. 2023 Apr 1;48(4):289-295. doi: 10.1097/RLU.0000000000004566. Epub 2023 Jan 20.
We aimed to compare the diagnostic performance of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in primary prostate cancer (PCa) patients.
Thirty untreated primary PCa patients were enrolled. Each patient underwent 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT within a week. In addition to visual analysis, SUV was measured for semiquantitative comparison and correlation analysis.
68 Ga-P16-093 PET/CT detected more positive tumors than 68 Ga-PSMA-617 PET/CT (67 vs 56, P = 0.002), especially for intraprostatic lesions (29 vs 24, P = 0.025) and lymph node metastases (23 vs 17, P = 0.034). Further, 68 Ga-P16-093 PET/CT exhibited significantly higher SUV max of matched tumors (18.3 ± 14.4 vs 13.9 ± 11.8, P < 0.001). Besides, the SUV max of high-risk patients (based on D'Amico classification) on 68 Ga-P16-093 PET/CT was significantly higher than that of low- and intermediate-risk PCa patients (20.9 ± 9.9 vs 8.9 ± 9.1 vs 10.1 ± 5.2, P = 0.007). The SUV max of tumor measured by 68 Ga-P16-093 PET/CT had a moderate association with biopsy Gleason score ( r = 0.462, P = 0.005) and prostate-specific antigen value ( r = 0.491, P = 0.002), and significantly correlated with PSMA expression ( r = 0.732, P < 0.001).
68 Ga-P16-093 PET/CT exhibited higher tumor uptake and potentially better tumor detection capability than 68 Ga-PSMA-617 PET/CT, which suggested that 68 Ga-P16-093 may be more suitable in the diagnosis and staging of primary PCa patients.
我们旨在比较 68Ga-P16-093 和 68Ga-PSMA-617 PET/CT 在原发性前列腺癌（PCa）患者中的诊断性能。
共纳入 30 例未经治疗的原发性 PCa 患者。每位患者在一周内接受 68Ga-P16-093 和 68Ga-PSMA-617 PET/CT 检查。除了进行视觉分析外，还测量了 SUV 以进行半定量比较和相关性分析。
68Ga-P16-093 PET/CT 比 68Ga-PSMA-617 PET/CT 检测到更多的阳性肿瘤（67 个 vs 56 个，P = 0.002），尤其是对于前列腺内病变（29 个 vs 24 个，P = 0.025）和淋巴结转移（23 个 vs 17 个，P = 0.034）。此外，68Ga-P16-093 PET/CT 显示匹配肿瘤的 SUVmax 显著更高（18.3 ± 14.4 vs 13.9 ± 11.8，P < 0.001）。此外，68Ga-P16-093 PET/CT 上高危患者（基于 D'Amico 分类）的 SUVmax 显著高于低危和中危 PCa 患者（20.9 ± 9.9 vs 8.9 ± 9.1 vs 10.1 ± 5.2，P = 0.007）。68Ga-P16-093 PET/CT 测量的肿瘤 SUVmax 与活检 Gleason 评分（r = 0.462，P = 0.005）和前列腺特异性抗原值（r = 0.491，P = 0.002）具有中度相关性，并且与 PSMA 表达显著相关（r = 0.732，P < 0.001）。
与 68Ga-PSMA-617 PET/CT 相比，68Ga-P16-093 PET/CT 显示出更高的肿瘤摄取和潜在更好的肿瘤检测能力，这表明 68Ga-P16-093 可能更适合原发性 PCa 患者的诊断和分期。
